114 related articles for article (PubMed ID: 2379533)
1. Multiple dose trial of the thromboxane synthase inhibitor furegrelate in normal subjects.
Mohrland JS; Vander Lugt JT; Lakings DB
Eur J Clin Pharmacol; 1990; 38(5):485-8. PubMed ID: 2379533
[TBL] [Abstract][Full Text] [Related]
2. Thromboxane synthase activity and platelet function after furegrelate administration in man.
Mohrland JS; Vander Lugt JT; Gorman RR; Lakings DB
J Clin Pharmacol; 1989 Jan; 29(1):53-8. PubMed ID: 2708549
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic studies following single and multiple doses of rolafagrel, a novel inhibitor of thromboxane synthase, in normal volunteers.
Gatti G; Bartoli A; Bertin D; Strolin-Benedetti M; Perucca E
Eur J Clin Pharmacol; 1994; 47(3):275-80. PubMed ID: 7867681
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
5. Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
Mikashima H; Ochi H; Muramoto Y; Yasuda H; Tsuruta M; Maruyama Y
Thromb Res; 1986 Aug; 43(4):455-68. PubMed ID: 3094191
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
[TBL] [Abstract][Full Text] [Related]
7. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.
FitzGerald GA; Brash AR; Oates JA; Pedersen AK
J Clin Invest; 1983 Oct; 72(4):1336-43. PubMed ID: 6355181
[TBL] [Abstract][Full Text] [Related]
8. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
9. Effects of very low dose and enteric-coated acetylsalicylic acid on prostacyclin and thromboxane formation and on bleeding time in healthy subjects.
Bode-Böger SM; Böger RH; Schubert M; Frölich JC
Eur J Clin Pharmacol; 1998; 54(9-10):707-14. PubMed ID: 9923572
[TBL] [Abstract][Full Text] [Related]
10. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets.
Berrettini M; De Cunto M; Parise P; Grasselli S; Nenci GG
Eur J Clin Pharmacol; 1990; 39(5):495-500. PubMed ID: 1963845
[TBL] [Abstract][Full Text] [Related]
11. Selective and nonselective inhibition of thromboxane formation.
FitzGerald GA; Oates JA
Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554
[TBL] [Abstract][Full Text] [Related]
12. Characterization of N,N'-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets.
Gresele P; Deckmyn H; Arnout J; Nenci GG; Vermylen J
Thromb Haemost; 1989 Jun; 61(3):479-84. PubMed ID: 2552606
[TBL] [Abstract][Full Text] [Related]
13. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.
Onoda JM; Sloane BF; Honn KV
Thromb Res; 1984 Jun; 34(5):367-78. PubMed ID: 6377570
[TBL] [Abstract][Full Text] [Related]
14. Sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate (U-63557A), a new, selective thromboxane synthase inhibitor: intravenous and oral pharmacokinetics in dogs and correlations with ex situ thromboxane B2 production.
Wynalda MA; Liggett WF; Fitzpatrick FA
Prostaglandins; 1983 Aug; 26(2):311-24. PubMed ID: 6685888
[TBL] [Abstract][Full Text] [Related]
15. Effects of camonagrel, a selective inhibitor of platelet thromboxane synthase, on the platelet-subendothelium interaction.
Villalobos MA; De La Cruz JP; Escalante R; Arrebola MM; Guerrero A; Sánchez de la Cuesta F
Pharmacology; 2003 Sep; 69(1):44-50. PubMed ID: 12886030
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of Y-20811, a new long-acting thromboxane synthetase inhibitor by oral administration.
Nakashima M; Uematsu T; Takiguchi Y; Mizuno A; Kanamaru M
J Clin Pharmacol; 1989 Jun; 29(6):568-76. PubMed ID: 2754025
[TBL] [Abstract][Full Text] [Related]
17. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
[TBL] [Abstract][Full Text] [Related]
18. Effect of cetiedil on platelet aggregation and thromboxane synthesis.
Yamaguchi A; Asakura T; Tanoue K; Yamazaki H
Thromb Res; 1985 Feb; 37(3):391-400. PubMed ID: 2986312
[TBL] [Abstract][Full Text] [Related]
19. Acetyl glycerylphosphorylcholine inhibition of prostaglandin I2-stimulated adenosine 3',5'-cyclic monophosphate levels in human platelets. Evidence for thromboxane A2 dependence.
Miller OV; Ayer DE; Gorman RR
Biochim Biophys Acta; 1982 Jun; 711(3):445-51. PubMed ID: 6285985
[TBL] [Abstract][Full Text] [Related]
20. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
